Strategic appointment to drive clinical development

Eleva, a leader in biologics innovation utilising its breakthrough moss-based platform, has announced the appointment of Dr Martin Bauer, MD, as its new Chief Medical Officer. This appointment comes as the company prepares to advance its pipeline, including the highly anticipated Factor H (CPV-104) program, set to enter clinical trials in 2025 for C3 Glomerulopathy (C3G), with dry Age-Related Macular Degeneration (AMD) identified as a potential second indication.

Dr Bauer brings over 20 years of clinical development expertise to Eleva, having held senior leadership roles at several prominent organisations including Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. His background spans a range of therapeutic areas, with experience in drug development across multiple modalities. Dr Bauer is board-certified in Anaesthesiology, Rescue Medicine, and Medical Informatics, and has extensive experience in academic hospitals.

Björn Cochlovius, PhD, CEO of Eleva, stated: “With the upcoming clinical trial launch for our second fully owned drug development program, we are excited to bring on Dr Bauer as Chief Medical Officer. His extensive background in clinical development will be invaluable as we continue to advance our pipeline and grow as a drug development organisation.”

Dr Bauer expressed his enthusiasm for the role, noting: “I’m thrilled to support Eleva’s exciting journey as we advance our pipeline, particularly the Factor H program, which offers a novel therapeutic approach with significant potential in treating C3G and potentially other indications. Eleva’s commitment to developing differentiated therapies aligns with my passion for advancing clinical solutions that address unmet needs.”

As Eleva moves forward with its clinical development programs, Dr Bauer’s leadership will play a critical role in shaping the company’s strategic direction and advancing its innovative therapies.

More information online